生物活性玻璃复合自体骨髓移植治疗青少年纯性骨囊肿

[目的] 探讨牛物活性玻璃复合自体骨髓移植治疗青少年单纯性骨囊肿的疗效.[方法] 2005年4月～2007年10月手术治疗青少年单纯性骨囊肿16例,其中男10例,女6例;平均年龄18.5岁(12～30岁).肱骨近端8例,股骨近端5例,胫骨上端2例,桡骨远端1例.囊壁彻底搔刮处理后,将适最的生物活性玻璃(bioactive glass,BG)复合取得的自体骨髓紧密填塞入骨缺损空腔,5例合并移位的病理性骨折予钢板或髓内钉固定.[结果] 治疗后6个月内X线片显示所有囊腔骨化,平均愈合时间18周,随访6～32个月,平均18个月,未见明显并发症发生,无病例复发.[结论] 生物活性玻璃复合自体骨髓移植治疗青少年单纯性骨囊肿创伤小、安全、操作简单,疗效满意.     

Bone formation in rabbit cancellous bone defects filled with bioactive glass granules

We examined new bone formation after filling cancellous bone defects with bioactive glass (BG) in granular form. Cylindrical defects in the trochanter area of 18 rabbit femora were filled with BG granules (diameter 600-830 μm) and compared with similar defects filled with morcellized autogenous bone. New bone formation and surface reaction of BG particles were evaluated by light microscopy, histomorphometry, and scanning electron microscopy. The chemical profile at the bone- material interface was studied by energy dispersive x-ray analysis (EDXA). In the BG group, 41, 32, and 38 percent of the defects were filled with new bone after 3, 6, and 12 weeks, respectively. The corresponding figures for the autogenous bone group were 36, 29, and 34 percent. The thickness of the reaction layer on the glass surface increased from 82 to 163 μm during the observation periods. An intimate contact without intervening soft tissue between new bone lamellae and BG granules was a constant finding. EDXA showed a chemical continuum between the granules and the new bone. No adverse reactions related to BG were observed. BG is a promising material for filling cancellous bone defects.     

辛伐他汀联合阿仑膦酸钠对去卵巢骨质疏松大鼠骨代谢的影响

目的探讨辛伐他汀联合阿仑膦酸钠干预对去卵巢大鼠骨质疏松骨代谢的影响。方法 60只雌性SD大鼠随机平均分为5组:假手术组、去势组、辛伐他汀组、阿仑膦酸钠组、联合药物组,首先构建去卵巢大鼠骨质疏松性模型。分别检测骨代谢相关生化指标、氧化应激生化指标和骨组织骨密度(bone mineral density,BMD),HE染色观察骨组织形态学。结果去势组大鼠血清Ca、P、SOD、CAT和骨组织BMD均较假手术组显著降低(P0.05),辛伐他汀组、阿仑膦酸钠组、联合药物组上述指标均较去势组升高,以联合用药组升高最显著(P0.05)。去势组大鼠血清ALP、BGP、PICP、TRAP、GLA、ICIP和MDA较假手术组均显著增高(P0.05),辛伐他汀组、阿仑膦酸钠组、联合药物组上述指标较去势组均降低,以联合用药组降低最显著(P0.05)。去势组股骨骨小梁明显稀疏,连接不完整,大量纤维组织,髓腔内大量空泡状脂肪细胞。联合药物组骨小梁数目明显增多,结构较完整,粗细均匀致密,连接成网状。结论辛伐他汀联合阿仑膦酸钠通过调节去卵巢大鼠骨代谢,抗氧化应激,增加骨密度,改善骨组织结构,发挥抗骨质疏松作用。     

Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats.

Targeted remodeling of fatigue-injured bone involves activation of osteoclastic resorption followed by local bone formation by osteoblasts. We studied the effect of parenteral alendronate (ALN) on bone adaptation to cyclic fatigue. The ulnae of 140 rats were cyclically loaded unilaterally until 40% loss of stiffness developed. We used eight treatment groups: (1) baseline control; (2) vehicle (sterile saline) and (3) alendronate before fatigue, no adaptation (Pre-VEH, Pre-ALN, respectively); (4) vehicle and (5) alendronate during adaptation to fatigue (Post-VEH, Post-ALN, respectively); (6) vehicle before fatigue and during adaptation (Pre-VEH/Post-VEH); (7) alendronate before fatigue and vehicle during adaptation (Pre-ALN/Post-VEH); (8) alendronate before fatigue and during adaptation (Pre-ALN/Post-ALN). Bones from half the rats/group were tested mechanically; remaining bones were examined histologically. The following variables were quantified: volumetric bone mineral density (vBMD); ultimate force (F(u)); stiffness (S); work-to-failure (U); cortical area (Ct.Ar); new woven bone tissue area (Ne.Wo.B.T.Ar); resorption space density (Rs.N/T.Ar). Microcracking was only seen in fatigue-loaded ulnae. A significant effect of alendronate on vBMD was not found. Preemptive treatment with alendronate did not protect the ulna from structural degradation during fatigue. After fatigue, recovery of mechanical properties by adaptation occurred; here a significant alendronate effect was not found. An alendronate-specific effect on adaptive Ne.Wo.B.T.Ar was not found. In the fatigue-loaded ulna, Rs.N/T.Ar was increased in vehicle-treated adapted groups, but not alendronate-treated adapted groups, when compared with baseline control. These data suggest that short-term alendronate treatment does not protect bone from fatigue in this model. Inhibition of remodeling may reduce microcrack repair over time.     

载阿仑膦酸钠骨水泥抑制钛磨屑诱导的假体周围骨溶解

目的 比较载阿仑膦酸钠丙烯酸骨水泥与皮下注射阿仑膦酸钠抑制钛磨眉诱导的骨溶解的效果.方法 48只成年雄性新西兰兔随机均分为无钛磨屑且无阿仑膦酸钠组(A组),有钛磨屑注射且无阿仑膦酸钠组(B组),钛磨屑分别注射0.1%、0.5%、1.0%载阿仑膦酸钠丙烯酸骨水泥组(C、I)、E组),钛磨屑注射且皮下手射阿仑膦酸钠组(F组),每组8只.将载阿仑膦酸钠骨水泥植入兔股骨远端.制备磨屑诱导骨溶解动物模型.术后8周对股骨行组织形态学分析、骨密度(bone mineral density,BMD)测定及界面力学测试结果 B组假体周围可见明显的骨溶解,而C、D、E、F组骨溶解明显少于B组.B组假体周围BMD和骨-骨水泥界面抗剪强度分别较A组下降17%和56%;D组假体周围BMD和界面抗剪强度较B组分别增加29%和62%;E组假体周围BMD和界画抗剪强度较B组分别增加37%和29%;F组假体周围BMD和界面抗剪强度较B组分别增加51%和69%;C组、D组、E组分别与F组比较,假体周围BMD和界面抗剪强度的差异均无统计学意义.结论 载阿仑瞵酸钠丙烯酸骨水泥与皮下注射阿仑瞵酸钠均可在一定程度上抑制磨屑诱导的骨吸收,增强界画抗剪强度.     

Effect of bone marrow mononuclear phagocytes on the bone matrix-induced bone formation in rats

Experimental ulnar bone defects in rats were grafted with freshly isolated whole bone marrow cells; bone marrow mononuclear phagocytes (macrophages); or both types of marrow cell preparations in combination with demineralized bone matrix gelatin (BMG). In the absence of BMG, the osteogenic performance of the marrow cell preparations was superior to that of the macrophages. In the presence of BMG (composite grafts), their osteogenic potential was nearly identical and significantly improved the level of bone formation stimulated by implants of BMG alone. The results encourage speculation and further research on sequential activities of bone marrow monocyte-macrophage (osteoclast) lineages and marrow stromal (osteoprogenitor) cell in bone morphogenetic protein (BMP)-induced regeneration.     

阿仑膦酸钠对绝经后骨质疏松症患者骨代谢指标的影响

目的观察抗骨吸收药物双膦酸盐对绝经后骨质疏松症患者骨代谢状态的影响。方法本研究为回顾性研究,共收集在我院骨质疏松门诊数据库中临床资料完整的女性绝经后骨质疏松症患者152例,其中阿仑膦酸钠治疗组93例(A组),每周给予阿仑膦酸钠70 mg,一次口服;未服用阿仑膦酸钠对照组59例(B组)。分别观察治疗前和治疗后3、6、12个月骨转换生化指标:骨特异性碱性磷酸酶(BAP)、抗酒石酸酸性磷酸酶(TRAP-5b)及25羟维生素D(25(OH)VD)的变化。结果 A组患者经阿仑膦酸钠治疗3个月后BAP和TRAP-5b水平分别较治疗前下降30.60%和32.95%(P0.001)治疗6个月时完全降至女性绝经前水平,并一直维持在此水平至治疗后12个月。B组患者治疗前后BAP和TRAP-5b水平差异无统计学意义。结论绝经后骨质疏松症患者骨代谢处于高转换状态,其BAP及TRAP-5b水平较绝经前明显升高;经阿仑膦酸钠治疗3个月后高转换状态可以明显改善,骨转换指标BAP和TRAP-5b水平回落到绝经前水平。     

电针对去卵巢大鼠骨形成及骨吸收活性的影响

目的研究电针刺对去卵巢骨质疏松模型大鼠的全身骨密度(BMD)、骨矿物含量(BMC)及其血清对体外培养成骨细胞的骨形成因子骨钙素(OPG)和骨吸收因子(RANKL)蛋白表达的影响。方法选取SPF级2月龄SD雌性大鼠40只,随机分为空白组、电针组、药物组和模型组,每组10只。其中空白组不做任何处理,后3组采用手术方法切除双侧卵巢。饲养3个月后,骨密度检测结果显示造模成功。随后药物组大鼠灌胃服用戊酸雌二醇3个疗程,电针组大鼠采用针刺后通电治疗3个疗程并服用药物组相同体积的蒸馏水,模型组服用相应体积的蒸馏水,空白组常规饲养。各组大鼠于SPF级实验室处理3个月后,双能X射线骨密度仪检测全身骨密度和骨矿含量。随后,水合氯醛麻醉各组大鼠,心脏采血,各组血液分别经滤网过滤、56℃水浴处理后加入体外培养的大鼠成骨细胞培养液中,处理3d后多聚甲醛固定成骨细胞,采用免疫细胞化学染色法检测成骨细胞内OPG、RANKL蛋白的表达量。结果与空白组相比,模型组大鼠BMD,BMC显著降低(P0.05),服用药物或针刺处理后,BMD和BMC显著增高(P0.05),与模型组相比差异具有统计学意义。各组大鼠血清处理成骨细胞后,模型组骨形成指标OPG蛋白表达量较低,经药物或针刺后,OPG蛋白表达量显著升高(P0.01)。此外,模型组骨吸收指标RANKL的表达量较高,经药物和针刺处理后,RANKL蛋白表达量显著下降(P0.01)。结论针刺能有效升高大鼠BMD和BMC,同时针刺处理后的大鼠血清具有很好的促进骨形成和抑制骨吸收的能力。     

Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats

Background  

Avascular necrosis of bone (osteonecrosis) can cause structural failure and subsequent deformation, leading to joint dysfunction and pain. Structural failure is the result of resorption of necrotic bone during revascularization, before new bone has formed or consolidated enough for loadbearing. Bone resorption can be reduced by bisphosphonates. If resorption of the necrotic bone could be reduced during the revascularization phase until sufficient new bone has formed, it would appear that structural failure could be avoided.     

甲状旁腺激素联合阿仑膦酸钠对大鼠骨质疏松性骨折骨痂血管形成的影响

目的探讨甲状旁腺激素联合阿仑膦酸钠对大鼠骨质疏松性骨折骨痂血管形成及骨折愈合的影响。方法 75只雌性SD大鼠随机分为5组:假手术组、去势组、甲状旁腺素组、阿仑膦酸钠组、联合用药组,每组15只,首先行双侧卵巢切除术,术后4周行右侧股骨干骨折髓内固定术,以构建大鼠骨质疏松性骨折动物模型。观察并评估骨折愈合,检测骨痂生物力学和骨密度(bone mineral density,BMD),检测血清血管内皮生长因子(vascular endothelial growth factor,VEGF)和骨形成发生蛋白-2(bone morphogenetic protein-2,BMP-2)浓度,观察骨痂形态结构,检测骨痂VEGF表达。结果去势组较假手术组骨折愈合评分、骨痂生物力学强度、骨痂BMD、血清BMP-2和VEGF浓度、骨痂VEGF蛋白表达、骨痂微血管数均显著降低(P0.05),甲状旁腺素组、阿仑膦酸钠组、联合用药组较去势组上述指标均升高,其中以联合用药组升高最显著(P0.05)。结论甲状旁腺激素联合阿仑膦酸钠通过介导VEGF,上调BMP-2表达,促进骨质疏松性骨折大鼠骨痂血管形成,增加骨密度,改善生物力学强度及骨组织形态学,加快骨折愈合。     

Effect of soft laser and bioactive glass on bone regeneration in the treatment of bone defects (an experimental study)

This study aimed to investigate the influence of low-power gallium–aluminium–arsenide (GaAlAs) laser [830 nm, continuous wave (CW), 40 mW and fluence 4 J/cm²] on the healing of surgically created bone defects in rats treated with bioactive glass graft material. Surgical bone defects were created in the mandibles of 36 Wistar rats divided into two groups, each consisting of 18 rats. Group I was treated with bioactive glass plus laser irradiation. Group II was treated with graft material only. The animals were killed at 4 weeks, 8 weeks and 12 weeks postoperatively for histological examination. Laser irradiation had significantly accelerated bone healing at 4 weeks and 8 weeks in comparison with that at the sites not irradiated. However at 12 weeks, complete healing of the defects had occurred with no difference detected. Our results have confirmed the positive effect of soft laser in accelerating bone regeneration.     

谷康泰灵对骨质疏松模型大鼠骨形成和骨吸收功能的影响

目的　观察药物谷康泰灵对骨质疏松 (OP)模型大鼠骨形成和骨吸收功能的影响 ,为其临床治疗骨质疏松提供实验依据。方法　SD大鼠 4 4只 ,随机分为正常组 (13只 )和骨质疏松模型组 (31只 )。以维甲酸 80mg·kg- 1 ·d- 1 灌胃 15d,诱导OP模型。模型复制成功后 ,各组处死 5只 ,正常组 (8只 )继续观察 ,模型组又随机分为无措施对照组 (8只 )、谷康泰灵治疗组 (10只 ,0 0 8mg·kg- 1 ·d- 1 谷康泰灵腹腔注射 )和雌二醇治疗组 (8只 ,每只 0 0 5mg,每周 3次苯甲酸雌二醇腹腔注射 )。治疗期 30d。观察股骨松质骨区成骨细胞及破骨细胞数量和血清中AKP、TRAP活性变化。结果　与正常组相比 ,维甲酸诱导的OP模型大鼠股骨松质骨区成骨细胞功能活跃 ,数量变化不大 ;破骨细胞数量、活跃程度显著增加 ;血清中AKP和TRAP明显增高。谷康泰灵治疗后 ,OP大鼠活跃成骨细胞数量明显增加 ,破骨细胞数量显著减少 ,血清AKP活性明显增高 ,TRAP活性下降。结论　谷康泰灵对OP大鼠骨形成和骨吸收功能有显著影响 ,可刺激成骨细胞的产生增加成骨细胞的活性 ,减少破骨细胞的数量抑制破骨细胞的活性。     

Effect of alendronate on fracture healing and bone remodeling in dogs

To examine the effect of alendronate (4-amino-1-hydroxybutylidene bisphosphonate) on fracture repair, the drug was given to mature beagle dogs orogastrically at 2 mg/kg/day for 9 weeks preceding fracture, 16 weeks after fracture, or both before and after fracture (25 weeks). A transverse mid-diaphyseal fracture of the right radius was surgically induced and was stabilized by external coaptation splinting. Fracture healing and bone remodeling were evaluated by radiography, gross and histological examination, and bone histomorphometry. The mechanical properties of the fracture callus were determined by a four-point bending test. Radiographs and gross and microscopic examination demonstrated normal bone healing at the fracture site in all dogs. In dogs that received alendronate during the fracture healing period, at 16 weeks the calluses were approximately 2–3 times larger than those in dogs that received a placebo during the healing period. This is consistent with slower callus bone remodeling, an expected pharmacological effect of the compound. Bone histomorphometry demonstrated that treatment with alendronate did not inhibit bone formation or mineralization. Mechanical testing showed that the ultimate load at failure and the flexural rigidity of both the fractured and contralateral intact bone were unaffected by treatment with alendronate. Therefore, in this study, treatment with alendronate before or during fracture healing, or both, resulted in no adverse effects on the union, strength, or mineralization of bone in mature beagle dogs.     

Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis

Alendronate has recently been approved for the prevention and treatment of postmenopausal osteoporosis, and its efficacy has been demonstrated in many Western countries. Our present study was performed to evaluate the effect of alendronate on bone mineral density (BMD) and its tolerability in Thais. Eighty postmenopausal women with osteoporosis participated in this study. After giving informed consent, the subjects were randomly allocated either 10mg alendronate or placebo in a double-blind fashion. All patients received a supplement of 500mg elemental calcium daily. BMD at the lumbar spine, femoral neck, and distal forearm was measured at baseline and 6 and 12 months after treatment. Biochemical markers of bone resorption were determined at baseline and 6 months after treatment. Baseline characteristics were similar in both alendronate- and placebo-treated groups. Ten subjects discontinued the study. Of 70 subjects, 32 received 10mg alendronate daily and the remaining subjects received placebo. At 1 year, BMD in the alendronate-treated group had increased from baseline by 9.2%, 4.6%, and 3.1% at lumbar spine, femoral neck, and distal forearm, respectively. These percentages were greater than those in controls (4.1%, 0.6%, and 1.0%, respectively). Urinary N-terminal telopeptide (NTx)-I and serum C-terminal telopeptide (CTx)-I levels decreased in both groups after 6 months of treatment. However, more reduction was demonstrated in the alendronate-treated group (71.9% vs. 28.4%, P 0.01, and 84.7% vs. 33.1%, P 0.01, respectively). Compliance with treatment and drug tolerability were good in both alendronate and placebo groups. We concluded that treatment with alendronate 10mg daily for Thai postmenopausal women with osteoporosis significantly increased BMD at all skeletal sites and reduced biochemical markers of bone resorption. It was well tolerated without any serious side effects.     

Effect of platelet derived growth factor on heterotopic bone formation in rats

Platelet derived growth factor (PDGF) and induction of newly woven bone growth were studied in rats. PDGF (20 ng/mL) was administered continuously for 2 weeks via microosmotic pumps to 6-mm-long pieces of demineralized rat femur inserted into muscle pouches. Each rat had a control piece of demineralized bone inserted into the contralateral gluteal muscle. The samples were collected after 4 weeks, and wet and ash weight were recorded. Fourteen rats were evaluated. There were no differences as regards wet weights. PDGF increased the ash weights.     

Effect of platelet derived growth factor on heterotopic bone formation in rats

Platelet derived growth factor (PDGF) and induction of newly woven bone growth were studied in rats. PDGF (20 ng/mL) was administered continuously for 2 weeks via micro-osmotic pumps to 6-mm-long pieces of demineralized rat femur inserted into muscle pouches. Each rat had a control piece of demineralized bone inserted into the contralateral gluteal muscle. The samples were collected after 4 weeks, and wet and ash weight were recorded. Fourteen rats were evaluated. There were no differences as regards wet weights. PDGF increased the ash weights.